Ikonisys and BIO BRASIL BIOTECNOLOGIA strengthen partnership to expand cytology services in Brazil Page 1

Regulatory News:

Ikonisys (Euronext Growth Paris: ALIKO)a company specialized in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces that its wholly owned subsidiary Hospitex International has signed a Memorandum Of Understanding (MOU) with BIO BRASIL BIOTECNOLOGIA LTDA, a leading provider of anatomic pathology services in Brazil, marking a significant expansion of their collaboration in Brazil. This collaboration aims to increase the availability of diagnostic tools and improve healthcare outcomes in the state of São Paulo through the acquisition of additional advanced cytology equipment.

More specifically, the MOU outlines the acquisition of an additional 10 Cytofast Plus systems and 50,000 reagent kits by BIO BRASIL. This will expand the company’s diagnostic infrastructure, in addition to the 7 systems already deployed in partnership with Hospitex, to meet the growing demand for Pap tests and urinary cytology diagnostics in São Paulo. In addition, a pilot project of innovative fluorescence on the spot hybridization (FISH) technology will be performed in the centralized laboratory of BIO BRASIL to test the advanced diagnostic solution of Ikonisys for urinary cytology. This project aims to introduce innovative applications for LSiL (Low-grade Squamous Intraepithelial Lesions) and ASCUS (Atypical Squamous Cells of Undetermined Significance) in Pap tests. The system has already been successfully evaluated in collaboration with the City Hall of São Paulo.

As part of the agreement, BIO BRASIL will oversee the integration and operational deployment of the new equipment, provide staff training and promote accessibility of cytology services, while Ikonisys will supply the equipment and reagent kits, provide technical support and training, and collaborate on R&D initiatives. The partnership will last two years and aims to stimulate innovations in diagnostic pathology. Both companies are committed to completing an initial order of equipment and supplies by the end of 2024, to ensure rapid deployment in support of market needs.

The state of São Paulo offers a substantial market for cytology services. With almost 8 million women of cervical cancer screening age, preventive Pap tests have become a public health priority, with a current urban coverage of over 70%. In addition, the state of São Paulo reports approximately 20,000 new cases of bladder cancer each year, highlighting the growing demand for urinary cytology diagnostics.